8-K: Vicarious Surgical Faces NYSE Delisting Threat Due to Market Cap and Equity Deficit

Vicarious Surgical received a notice from the NYSE indicating non-compliance with continued listing standards due to its market capitalization and stockholders' equity falling below $50 million.

Summary

• Vicarious Surgical Inc. received a notice from the New York Stock Exchange (NYSE) on April 10, 2025, stating that it is not in compliance with Section 802.01B of the NYSE's Listed Company Manual.
• This non-compliance is due to the company's average global market capitalization being less than $50 million over a consecutive 30 trading-day period, and its stockholders' equity also being less than $50 million.
• As of April 9, 2025, the company's 30 trading-day average market capitalization was approximately $47.4 million, and its last reported stockholders' equity as of December 31, 2024, was approximately $46.7 million.
• Vicarious Surgical has 45 days from the notice to submit a plan to the NYSE outlining actions to regain compliance within 18 months (the Cure Period).
• The NYSE will then have 45 days to evaluate the plan.
• If the plan is accepted, the NYSE will review the company's compliance quarterly.
• If the plan is not accepted, or if the company fails to comply or meet the minimum standards by the end of the Cure Period, delisting procedures will be initiated.
• The company's Class A common stock will continue to be listed on the NYSE during the Cure Period, but will have a '.BC' designation to indicate non-compliance.
• The company is considering all available options to regain compliance with the NYSE's continued listing standards.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the NYSE notice and the risk of delisting, although the company is taking steps to address the issue.

Positives

• The notice does not immediately impact the listing of the company's Class A common stock.
• The company has a cure period of 18 months to regain compliance.
• The company is considering all available options to regain compliance.

Negatives

• The company's average market capitalization and stockholders' equity are below the NYSE's minimum requirements.
• The company's Class A common stock will trade with a '.BC' designation, which could negatively impact investor perception.
• Failure to submit or comply with a plan could lead to delisting from the NYSE.

Risks

• The company may not be able to develop a plan acceptable to the NYSE.
• The company may not be able to execute its plan and regain compliance within the 18-month cure period.
• The potential suspension of trading of the company's Class A common stock on the NYSE poses a risk.

Future Outlook

The company is focused on developing and executing a plan to regain compliance with NYSE listing standards within the 18-month cure period. The company is considering all available options to achieve this.

Management Comments

• The Company is considering all available options to regain compliance with NYSEs continued listing standards.

Industry Context

The robotic surgery industry is competitive, with companies like Intuitive Surgical leading the market. Vicarious Surgical's challenges highlight the difficulties smaller companies face in maintaining financial stability and meeting exchange listing requirements while developing and commercializing innovative technologies.

Comparison to Industry Standards

• Intuitive Surgical, a leader in the robotic surgery space, has a market capitalization significantly higher than Vicarious Surgical, reflecting its established market position and profitability.
• Other companies in the medical device sector, such as Stryker and Medtronic, also maintain strong financial metrics and compliance with exchange listing standards.
• Vicarious Surgical's current situation underscores the challenges faced by smaller, growth-stage companies in a capital-intensive industry.

Stakeholder Impact

• Shareholders may experience a decline in stock value due to the non-compliance notice and potential delisting.
• Employees may face uncertainty regarding the company's future.
• Customers and partners may be concerned about the company's ability to continue operations and support its products.

Next Steps

• The company must submit a plan to the NYSE within 45 days outlining how it will regain compliance.
• The NYSE will evaluate the plan within 45 days of receipt.
• The company must execute the plan and demonstrate compliance within 18 months.

Key Dates

Keywords

NYSE, delisting, market capitalization, stockholders equity, compliance, RBOT, Vicarious Surgical